Recent Updates
Recently added Catalysts

PCI-32765

Phase 2

B-cell Chronic Lymphocytic Leukemia | Small molecule | Oncology |AbbVie Inc.|Last Updated: May 27, 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials4
Total Enrollment436

FDA Designations

No designations recorded

Clinical trial landscape

PCI-32765 · 7 trials · 15 indications

Phase 2 3Phase 1 4
NCT01478581Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaMultiple Myeloma
COMPLETED92 Analytics
NCT01236391Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)Mantle Cell Lymphoma
COMPLETED115 Analytics
NCT01109069Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic Leukemia
COMPLETED199 Analytics
PHASE2COMPLETED
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Multiple MyelomaUnlock trial analytics
PHASE2COMPLETED
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell LymphomaUnlock trial analytics
PHASE2COMPLETED
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic LeukemiaUnlock trial analytics

Study Endpoints

Primary Endpoints

The Clinical Benefit Response (CBR)
From the date of first study treatment until disease progression per IMWG, up to 60 months

The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria

Percentage of Participants Achieving Response
The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a \>/= 50% decrease in the sum of the product of diameters of the target lesions, and \>/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions.

Number of Subjects With Adverse Events
30 days after last dose of study drug, continue up to 6 months

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.

Incidence of Prolonged Hematologic Toxicity Started in Cycle 1
From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Safety During Dose-Limiting Toxicity (DLT) Observation Period
56 days for Group 1 and 28 days for Group 2

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2

Number of Participants With Treatment Emergent Adverse Events (AEs)
From first dose to within 30 days of last dose of PCI-32765

Number of participants who had experienced at least one treatment emergent AEs.

Dose limiting toxicity assessment for each patient.
At the end of the first 35 day cycle
Adverse events
30 days after last dose of study drug
Pharmacokinetic/ Pharmacodynamic assessments
during Cycle 1

Secondary Endpoints

To Evaluate the Efficacy of PCI-32765 by Assessing ORR
From the date of first study treatment until disease progression per IMWG, up to 60 months
Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)
Procedure was performed up to 60 weeks.
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).
Procedure was performed up to 60 weeks.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1EXPERIMENTALPCI-32765 420 mg per day
Cohort 2EXPERIMENTALPCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
Cohort 3EXPERIMENTALPCI-32765 840 mg per day
Cohort 4EXPERIMENTALPCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
Participants received PCI-32765 560 mg dailyEXPERIMENTALParticipants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
PCI-32765EXPERIMENTAL -
PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)EXPERIMENTAL -
PCI-32765 plus bendamustine/rituximab (BR)EXPERIMENTAL -
Group 1EXPERIMENTALIn Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
Group 2EXPERIMENTALIn Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
Group 3EXPERIMENTALIn Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily

Interventions

NameTypeDescription
PCI-32765DRUG -
DexamethasoneDRUG -
ofatumumabDRUGper package insert as an IV infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Diagnosis of symptomatic MM with measurable disease, defined here as having at least one of the following: 1. Serum monoclonal protein (M-protein) ≥0.5 g/dL as determined by serum protein electrophoresis (SPEP) 2. Urine M-protein ≥200 mg/24 hrs 3. Serum free light chain...

Countries:United StatesGermanyPolandUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about PCI-32765

What is PCI-32765 used for?

PCI-32765 is an investigational small molecule being studied for use in multiple myeloma, B-cell lymphoma, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma. It is being developed by AbbVie Inc. (ABBV) and has completed four clinical trials in these oncology indications.

Who makes PCI-32765?

PCI-32765 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in the oncology therapeutic area, studied for B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma.

What phase is PCI-32765 in?

PCI-32765 has completed Phase 1 and Phase 2 clinical trials. The completed trials include Phase 1 studies in B-cell lymphoma, chronic lymphocytic leukemia, and combination regimens, as well as a Phase 2 study in mantle cell lymphoma. It remains investigational and is not FDA approved.

What clinical trials is PCI-32765 in?

PCI-32765 has completed four clinical trials: NCT00849654 in recurrent B-cell lymphoma, NCT01105247 in chronic lymphocytic leukemia, NCT01236391 in relapsed/refractory mantle cell lymphoma, and NCT01292135 combining PCI-32765 with FCR or BR regimens in chronic lymphocytic leukemia. All trials are completed.

Is PCI-32765 the same as ibrutinib?

PCI-32765 is the investigational name for the drug that is also known as ibrutinib. It is being developed by AbbVie Inc. (ABBV) for B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and B-cell lymphoma. The drug has completed Phase 1 and Phase 2 trials.